HCW Biologics Inc. (NASDAQ:HCWB) Sees Large Drop in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 543,700 shares, a drop of 34.9% from the February 13th total of 835,500 shares. Based on an average trading volume of 5,830,000 shares, the short-interest ratio is presently 0.1 days. Currently, 2.1% of the shares of the company are short sold.

HCW Biologics Trading Up 1.7 %

HCWB stock traded up $0.01 during mid-day trading on Friday, hitting $0.34. 101,220 shares of the company were exchanged, compared to its average volume of 7,581,969. The business has a 50 day simple moving average of $0.38 and a 200-day simple moving average of $0.46. The stock has a market capitalization of $15.14 million, a PE ratio of -0.34 and a beta of 0.71. HCW Biologics has a 1-year low of $0.21 and a 1-year high of $2.52.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.